Mvasi Approval History
- FDA approved: Yes (First approved September 14th, 2017)
- Brand name: Mvasi
- Generic name: bevacizumab-awwb
- Dosage form: Injection
- Company: Amgen Inc.
- Treatment for: Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer
Mvasi (bevacizumab-awwb) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer.
Development History and FDA Approval Process for Mvasi
|Sep 14, 2017||FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin|
|Nov 15, 2016||Amgen and Allergan Submit Biosimilar BLA for ABP 215 to U.S. FDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.